Standard BioTools (NASDAQ:LAB – Get Rating) will issue its quarterly earnings data after the market closes on Monday, August 8th. Parties that wish to listen to the company’s conference call can do so using this link.
Standard BioTools (NASDAQ:LAB – Get Rating) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($0.31) earnings per share for the quarter. Standard BioTools had a negative return on equity of 63.43% and a negative net margin of 93.89%. The company had revenue of $26.50 million for the quarter.
Standard BioTools Price Performance
Shares of NASDAQ LAB opened at $1.89 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.06 and a debt-to-equity ratio of 4.52. The business’s fifty day moving average is $1.71. Standard BioTools has a 1-year low of $1.28 and a 1-year high of $7.31. The firm has a market capitalization of $146.01 million, a P/E ratio of -1.24 and a beta of 1.20.
Insider Buying and Selling
Standard BioTools Company Profile
Standard BioTools Inc creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology.
- Get a free copy of the StockNews.com research report on Standard BioTools (LAB)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.